Overview

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

Status:
Completed

Trial end date:
2018-05-17

Target enrollment:

Participant gender:

Summary

This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of IV ETX2514SUL in patients with complicated urinary tract infections (cUTIs) who are otherwise relatively healthy.

Phase:

Phase 2

Details

Lead Sponsor:

Entasis Therapeutics

Treatments:

Cilastatin
Cilastatin, Imipenem Drug Combination
Imipenem
Sulbactam